ClinicalTrials.gg
RecruitingNCT06545851Updated Aug 13, 2024

Effects of an Automatic Oxygen Titration System in People With Hypoxemia During Exercise Training

An interventional study of Oxygen therapy - constant oxygen flow and Oxygen therapy - automatic titrating oxygen flow in Hypoxaemia and Chronic Lung Disease, sponsored by Schön Klinik Berchtesgadener Land. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-08-13.

Sponsored by Schön Klinik Berchtesgadener Land · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Hypoxia with a site in Germany — 4 open to participants now, 4 under way, 1 of them phase 3. Hypoxia · Germany.

Planned enrollment
28th of 30
15 · median 35
Started
2023
the only one that year
No phase
22 of 35
2 open now
Registered
35th of 35
by date
Lead sponsor
3 of 35
Schön Klinik Berchtesgadener Land

Among the 35 studies in Hypoxia with a site in Germany, this one is the 28th largest by planned enrollment of the 30 interventional ones that give a count, is the only one that started in 2023, is one of 22 with no phase, and was the 35th registered.

Hypoxia

1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.

Browse Hypoxia studies →

Open to participants now

4 of the 35 studies in Hypoxia with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Hypoxia with a site in Germany, or all of them as a file.
02

Study summary

Long-term oxygen therapy is a fundamental treatment modality for patients with chronic hypoxaemic lung disease. Typically, oxygen is administered at a constant flow rate. However, due to fluctuating activity levels, patients' oxygenation status can vary, potentially leading to oxygen desaturation and increased dyspnoea.

Emerging evidence suggests that automatic oxygen titration - a method of adjusting oxygen flow in response to current oxygen saturation - may have acute advantages over constant oxygen flow.

The primary objective of this study is to investigate the effect of automatic oxygen titration compared to prescribed constant oxygen flow rates on patients' perceived dyspnoea during exercise endurance training.

Read the detailed description

Rationale:

Hypoxaemia is common in people with chronic lung disease and can affect exercise tolerance. Oxygen therapy is then recommended.

Oxygen supplementation is usually delivered at constant oxygen flow rates. Only a few studies have investigated the short-term effects of automated oxygen delivery compared to a constant oxygen flow rate during exercise tests (e.g. 6-minute walk test, shuttle walk tests). These studies have shown that automatic oxygen delivery can lead to an acute increase in exercise capacity, including an improvement in the perception of breathlessness. The use of automated oxygen delivery during endurance exercise has not been studied. The most common reason for stopping prolonged exercise in patients with chronic lung disease is dyspnoea. Therefore, the use of automatic oxygen delivery in a pulmonary rehabilitation clinic could be beneficial in the context of personalised therapy for patients requiring oxygen if it further reduces dyspnoea, potentially enabling the patient to train their endurance even better.

Therefore, the primary aim of this study was to investigate whether the use of automatic oxygen supplementation versus constant oxygen supplementation has a different effect on the perception of dyspnoea in patients with hypoxaemia during endurance exercise.

Design:

This study is designed as a randomised, double-blind, controlled cross-over trial. Participants will first undergo a cycle-based peak work rate test to determine their individual maximal peak work rate. They then take part in two sets of five endurance training sessions. One set is performed with a constant oxygen flow prescribed for each participant, while the other uses automatic oxygen titration. The order in which these two sessions are performed is randomised.

03

Conditions studied

  • Hypoxaemia
  • Chronic Lung Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic lung disease
  • Hypoxemia (pO2\< 55mmHg) under room air conditions (rest or during exercise) or SpO2\<88% during exercise
  • established Long-term oxygen therapy or given indication for a Long-term oxygen therapy/ supplemental oxygen therapy for exercise
  • Age: 18 to 80 years
  • Participation in an inpatient pulmonary rehabilitation program (Schoen Klinik BGL, Germany)
  • Written

Exclusion criteria

Exclusion Criteria:

  • Acute exacerbation of underlying pulmonary disease requiring cessation of exercise training.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Excercise Training Order A and B

    The first series of five exercise trainings (A) involves supplemental oxygen therapy, with automatically titrated oxygen flow rates to maintain an oxygen saturation of 90-94% (A). The second series of five exercise trainings employs supplemental oxygen therapy with constant flow rates (B), as prescribed.

    Other: Oxygen therapy - constant oxygen flow · Other: Oxygen therapy - automatic titrating oxygen flow

  • Experimental
    Excercise Training Order B and A

    The first series of five exercise trainings employs supplemental oxygen therapy with constant flow rates (B), as prescribed.The second five series of five exercise trainings involves supplemental oxygen therapy, with automatically titrated oxygen flow rates to maintain an oxygen saturation of 90-94% (A).

    Other: Oxygen therapy - constant oxygen flow · Other: Oxygen therapy - automatic titrating oxygen flow

Interventions

  • OtherOxygen therapy - constant oxygen flow

    During five exercise training sessions, oxygen therapy is delivered via prescribed constant oxygen flow

  • OtherOxygen therapy - automatic titrating oxygen flow

    During five exercise sessions, oxygen therapy is delivered via an automatically titrated oxygen flow rate to maintain an SpO2 target of 90-94%.

06

What researchers measure

Primary outcomes

  1. Dyspnea

    Change of dyspnea sensation rated by modified Borg scale (0 to 10) taken before and after exercise training

    Time frame: Day 1 to 5 and 6 to 10

Secondary outcomes

  1. Change of oxygen saturation (SpO2) during exercise training

    SpO2 measured by continuous transcutaneous recordung via Sentec-Digital Monitor® (Sentec, Therwil, Switzerland).

    Time frame: Day 1 to 5 and 6 to 10

  2. Change of transcutaneous partial CO2 pressure (TcPCO2) during exercise training

    TcPCO2 measured by continuous transcutaneous recording via Sentec-Digital Monitor® (Sentec, Therwil, Switzerland)

    Time frame: Day 1 to 5 and 6 to 10

  3. Change of heart rate during exercise training

    Heart rate measured by continuous transcutaneous recordung via Sentec-Digital Monitor® (Sentec, Therwil, Switzerland).

    Time frame: Day 1 to 5 and 6 to 10

  4. Change of capillary partial pressure of CO2 (pCO2) during exercise training

    pCO2 measured by capillary blood gases taken before and after the exercise training

    Time frame: Day 1 to 5 and 6 to 10

  5. Change of capillary partial pressure of O2 (pO2) during exercise training

    pO2 measured by capillary blood gases taken before and after the exercise training

    Time frame: Day 1 to 5 and 6 to 10

  6. Change of inspiratory capacity (IC) during exercise training

    IC measured by Spirometry taken before and after exercise training via SpiroSense Pro® (Pari, Starnberg, Germany)

    Time frame: Day 1 to 5 and 6 to 10

  7. Time to desaturation (SpO2 <=90%) and to severe desaturation (SpO2 <=85%) during exercise training

    SpO2 measured by continuous transcutaneous recordung via Sentec-Digital Monitor® (Sentec, Therwil, Switzerland)

    Time frame: Day 1 to 5 and 6 to 10

  8. Assessment of leg fatigue via BORG scale

    Change of leg fatigue assessed by modified Borg scale (0 to 10) taken before and after exercise training

    Time frame: Day 1 to 5 and 6 to 10

  9. Patients sensation regarding the oxygen delivery system

    Patients will be asked to rate their experienced comfort after Session 1 and Session 2 via a 5-point Likert Skale: strongly agree, agree, neutral, disagree, strongly disagree

    Time frame: Day 5 and 10

07

Study locations

1 of 1 sites recruiting
  • Klinikum Berchtesgadener Land, Schön Kliniken
    Schönau a.Königssee, Bavaria 83471, Germany
    Recruiting
08

References and documents

Publications

  • Kofod LM, Westerdahl E, Kristensen MT, Brocki BC, Ringbaek T, Hansen EF. Effect of Automated Oxygen Titration during Walking on Dyspnea and Endurance in Chronic Hypoxemic Patients with COPD: A Randomized Crossover Trial. J Clin Med. 2021 Oct 20;10(21):4820. doi: 10.3390/jcm10214820. PubMed 34768338 ↗
  • Schneeberger T, Jarosch I, Leitl D, Gloeckl R, Hitzl W, Dennis CJ, Geyer T, Criee CP, Koczulla AR, Kenn K. Automatic oxygen titration versus constant oxygen flow rates during walking in COPD: a randomised controlled, double-blind, crossover trial. Thorax. 2023 Apr;78(4):326-334. doi: 10.1136/thoraxjnl-2020-216509. Epub 2021 Oct 16. PubMed 34656996 ↗
  • Vivodtzev I, L'Her E, Vottero G, Yankoff C, Tamisier R, Maltais F, Lellouche F, Pepin JL. Automated O2 titration improves exercise capacity in patients with hypercapnic chronic obstructive pulmonary disease: a randomised controlled cross-over trial. Thorax. 2019 Mar;74(3):298-301. doi: 10.1136/thoraxjnl-2018-211967. Epub 2018 Aug 30. PubMed 30166425 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Nov 2024, 15 months after the start.

Of 324 non-industry interventional studies with no phase under Hypoxia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's planned 15 months is above that.

Counting every sponsor, half of 354 studies reached it within 12 months; a quarter within 3 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2023
First posted
Aug 9, 2024
StartActual
Aug 14, 2023
Primary completionEst.
Nov 30, 2024
CompletionEst.
Nov 30, 2024
Last update
Aug 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06545851
Lead sponsor
Schön Klinik Berchtesgadener Land
Responsible party
Prof. Dr. Andreas Rembert Koczulla (Principal Investigator, Schön Klinik Berchtesgadener Land) — Principal investigator
First posted
Aug 9, 2024
Start date
Aug 14, 2023
Primary completion
Nov 30, 2024 (estimated)
Completion
Nov 30, 2024 (estimated)
Last update
Aug 13, 2024

Study contacts

Andreas Rembert Koczulla, Prof. Dr.
Contact
rkoczulla@schoen-klinik.de
0049-8652-932730
Andreas Rembert Koczulla, Prof. Dr.
principal investigator · Philipps University Marburg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion